

Martin Eichner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5925700/publications.pdf>

Version: 2024-02-01

21
papers

568
citations

623734

14
h-index

713466

21
g-index

24
all docs

24
docs citations

24
times ranked

949
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. <i>Nature Communications</i> , 2020, 11, 1335.	12.8	75
2	Direct and indirect effects of influenza vaccination. <i>BMC Infectious Diseases</i> , 2017, 17, 308.	2.9	57
3	Towards Translational ImmunoPET/MR Imaging of Invasive Pulmonary Aspergillosis: The Humanised Monoclonal Antibody JF5 Detects <i>Aspergillus</i> Lung Infections <i>In Vivo</i> . <i>Theranostics</i> , 2017, 7, 3398-3414.	10.0	52
4	The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. <i>BMC Infectious Diseases</i> , 2014, 14, 40.	2.9	43
5	4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany. <i>BMC Infectious Diseases</i> , 2014, 14, 365.	2.9	39
6	Polio emergence in Syria and Israel endangers Europe. <i>Lancet</i> , The, 2013, 382, 1777.	13.7	38
7	Model-Based Investigations of Different Vector-Related Intervention Strategies to Eliminate Visceral Leishmaniasis on the Indian Subcontinent. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2810.	3.0	37
8	Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model. <i>Pharmacoeconomics</i> , 2016, 34, 1299-1308.	3.3	34
9	Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. <i>European Journal of Health Economics</i> , 2015, 16, 471-488.	2.8	32
10	Prognostic Impact of Perineural Invasion in Cutaneous Squamous Cell Carcinoma: Results of a Prospective Study of 1,399 Tumors. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1968-1975.	0.7	29
11	Simulation studies to assess the long-term effects of Japan's change from trivalent to quadrivalent influenza vaccination. <i>Vaccine</i> , 2018, 36, 624-630.	3.8	22
12	Constantly high incidence of scarlet fever in Germany. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 499-500.	9.1	20
13	Risk factors for human <i>Leptospira</i> seropositivity in South Germany. <i>SpringerPlus</i> , 2016, 5, 1796.	1.2	19
14	Immunomodulatory role of reactive oxygen species and nitrogen species during T cell-driven neutrophil-enriched acute and chronic cutaneous delayed-type hypersensitivity reactions. <i>Theranostics</i> , 2021, 11, 470-490.	10.0	17
15	A Comparative pO ₂ Probe and [18F]-Fluoro-Azomycinarabino-Furanoside ([18F]FAZA) PET Study Reveals Anesthesia-Induced Impairment of Oxygenation and Perfusion in Tumor and Muscle. <i>PLoS ONE</i> , 2015, 10, e0124665.	2.5	15
16	Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany. <i>Journal of Medical Economics</i> , 2021, 24, 490-501.	2.1	12
17	Influence of social contact patterns and demographic factors on influenza simulation results. <i>BMC Infectious Diseases</i> , 2016, 16, 646.	2.9	11
18	Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium. <i>Paediatric Drugs</i> , 2016, 18, 303-318.	3.1	7

#	ARTICLE	IF	CITATIONS
19	Assessing direct and indirect effects of pediatric influenza vaccination in Germany by individual-based simulations. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 836-845.	3.3	4
20	Epidemiological analysis of 3,219 COVID-19 outbreaks in the state of Baden-Wuerttemberg, Germany. <i>Epidemiology and Infection</i> , 2021, 149, e101.	2.1	2
21	Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	3.3	2